Promising Study
February 1, 2011/Prepared FoodsMagazine -- Massachusetts General Hospital is conducting a new study to evaluate the effects of GanedenBC30Æ on individuals with Irritable Bowel Syndrome (IBS) and Major Depressive Disorder (MDD). Two previous trials demonstrated that GanedenBC30 was safe and effective in IBS, and preliminary data also show that GanedenBC30Æ modulates certain neurotransmitters. Ganeden Biotech, www.digestiveadvantage.com
Looking for a reprint of this article?
From high-res PDFs to custom plaques, order your copy today!
